Show simple item record

dc.contributor.author Peak, Emily
dc.contributor.author Chalmers, Iain W.
dc.contributor.author Hoffmann, Karl F.
dc.date.accessioned 2010-10-22T11:24:15Z
dc.date.available 2010-10-22T11:24:15Z
dc.date.issued 2010
dc.identifier.citation Peak, E., Chalmers, I. W., Hoffmann, K. F. (2010). Development and validation of a quantitative, high-throughput, fluorescent-based bioassay to detect Schistosoma viability. Neglected Tropical Diseases, 4(7): e759 en
dc.identifier.uri http://hdl.handle.net/2160/5836
dc.description Corresponding author - KFH en
dc.description.abstract Background: Schistosomiasis, caused by infection with the blood fluke Schistosoma, is responsible for greater than 200,000 human deaths per annum. Objective high-throughput screens for detecting novel anti-schistosomal targets will drive ‘genome to drug’ lead translational science at an unprecedented rate. Current methods for detecting schistosome viability rely on qualitative microscopic criteria, which require an understanding of parasite morphology, and most importantly, must be subjectively interpreted. These limitations, in the current state of the art, have significantly impeded progress into whole schistosome screening for next generation chemotherapies. Methodology/Principal Findings: We present here a microtiter plate-based method for reproducibly detecting schistosomula viability that takes advantage of the differential uptake of fluorophores (propidium iodide and fluorescein diacetate) by living organisms. We validate this high-throughput system in detecting schistosomula viability using auranofin (a known inhibitor of thioredoxin glutathione reductase), praziquantel and a range of small compounds with previouslydescribed (gambogic acid, sodium salinomycin, ethinyl estradiol, fluoxetidine hydrochloride, miconazole nitrate, chlorpromazine hydrochloride, amphotericin b, niclosamide) or suggested (bepridil, ciclopirox, rescinnamine, flucytosine, vinblastine and carbidopa) anti-schistosomal activities. This developed method is sensitive (200 schistosomula/well can be assayed), relevant to industrial (384-well microtiter plate compatibility) and academic (96-well microtiter plate compatibility) settings, translatable to functional genomics screens and drug assays, does not require a priori knowledge of schistosome biology and is quantitative. Conclusions/Significance: The wide-scale application of this fluorescence-based bioassay will greatly accelerate the objective identification of novel therapeutic lead targets/compounds to combat schistosomiasis. Adapting this bioassay for use with other parasitic worm species further offers an opportunity for great strides to be made against additional neglected tropical diseases of biomedical and veterinary importance. en
dc.description.sponsorship Wellcome Trust (WT084273 and WT078317), the Sandler Center for Basic Research in Parasitic Diseases and the Welsh Assembly Government Academic Expertise for Business (A4B) scheme en
dc.language.iso en en
dc.publisher PLOS en
dc.relation.isreferencedby http://www.plosntds.org/article/info%3Adoi%2F10.1371%2Fjournal.pntd.0000759 en
dc.title Development and Validation of a Quantitative, High-Throughput, Fluorescent-Based Bioassay to Detect Schistosoma Viability en
dc.type Text en
dc.type.publicationtype refereed published journal paper en
dc.identifier.duplicate True


Files in this item

Aside from theses and in the absence of a specific licence document on an item page, all works in Cadair are accessible under the CC BY-NC-ND Licence. AU theses and dissertations held on Cadair are made available for the purposes of private study and non-commercial research and brief extracts may be reproduced under fair dealing for the purpose of criticism or review. If you have any queries in relation to the re-use of material on Cadair, contact is@aber.ac.uk.

This item appears in the following Collection(s)

Show simple item record

Search Cadair


Advanced Search

Browse

Statistics